| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TRH |
| Uniprot No | P20396 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-242aa |
| 氨基酸序列 | MPGPWLLLALALTLNLTGVPGGRAQPEAAQQEAVTAAEHPGLDDFLRQVE RLLFLRENIQRLQGDQGEHSASQIFQSDWLSKRQHPGKREEEEEEGVEEE EEEEGGAVGPHKRQHPGRREDEASWSVDVTQHKRQHPGRRSPWLAYAVPK RQHPGRRLADPKAQRSWEEEEEEEEREEDLMPEKRQHPGKRALGGPCGPQ GAYGQAGLLLGLLDDLSRSQGAEEKRQHPGRRAAWVREPLEE |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TRH(促甲状腺激素释放激素)重组蛋白的参考文献示例(注：部分文献信息为模拟虚构，仅供格式参考)：
1. **文献名称**：*Expression and Purification of Recombinant Thyrotropin-Releasing Hormone (TRH) in Escherichia coli*
**作者**：Chen L, et al.
**摘要**：研究通过大肠杆菌表达系统高效表达TRH重组蛋白，优化了诱导条件和纯化步骤，采用亲和层析法获得高纯度产物，并验证其生物活性。
2. **文献名称**：*Functional Characterization of Recombinant TRH Produced in Yeast Expression Systems*
**作者**：Martinez R, et al.
**摘要**：利用毕赤酵母系统表达TRH，通过质谱和细胞活性实验证明重组蛋白能有效激活TRH受体，为大规模生产提供可行性方案。
3. **文献名称**：*Stability and Pharmacokinetic Analysis of Recombinant TRH in Animal Models*
**作者**：Sato K, et al.
**摘要**：评估重组TRH在小鼠模型中的稳定性及药代动力学，发现其半衰期较天然TRH显著延长，提示潜在治疗应用价值。
4. **文献名称**：*CRISPR/Cas9-mediated TRH Gene Editing Enhances Recombinant Protein Yield in Mammalian Cells*
**作者**：Wang Y, et al.
**摘要**：通过基因编辑技术优化CHO细胞中TRH重组蛋白的表达效率，产量提高3倍，并保留完整生物活性。
如需真实文献，建议通过PubMed或Google Scholar以“recombinant TRH protein”、“TRH expression”等关键词检索。
**Background of TRH Recombinant Protein**
Thyrotropin-releasing hormone (TRH), a tripeptide (pyroglutamyl-histidyl-prolineamide), is a hypothalamic neuropeptide critical in regulating the hypothalamic-pituitary-thyroid (HPT) axis. It stimulates the anterior pituitary gland to secrete thyroid-stimulating hormone (TSH), which in turn activates thyroid hormone production, influencing metabolism, growth, and neurological functions. TRH also exhibits extrasynaptic neurotransmitter roles, modulating arousal, mood, and autonomic functions.
Recombinant TRH protein is synthesized using biotechnological methods, typically through expression in bacterial or mammalian systems. By cloning the TRH-coding gene sequence into expression vectors, host cells (e.g., *E. coli* or CHO cells) are engineered to produce the peptide. Advanced purification techniques, such as affinity chromatography, ensure high purity and bioactivity.
The development of recombinant TRH addresses challenges in natural extraction, such as low yield and structural instability. Its applications span research and therapeutics. In research, recombinant TRH aids in studying HPT axis dysregulation, neurodegenerative diseases (e.g., Alzheimer’s), and psychiatric disorders linked to TRH receptor signaling. Clinically, it has potential in diagnosing thyroid dysfunction or treating conditions like hypothyroidism and depression.
Recent studies explore TRH’s neuroprotective properties, particularly in spinal cord injury and epilepsy models, highlighting its role beyond endocrine regulation. However, its short half-life and rapid degradation limit therapeutic use, prompting innovations in drug delivery systems, including nanoparticle encapsulation or peptide analogs.
Overall, recombinant TRH represents a vital tool for elucidating neuroendocrine mechanisms and developing targeted therapies, bridging gaps between peptide biology and clinical medicine.
×
